Cite
HARVARD Citation
Seiwert, T. et al. (2020). A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study. Cancer. 126 (14), pp. 3237-3243. [Online].